ASNRT — Arab Society of Nephrology and Renal Transplantation

Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial.

From 97 screened patients, we excluded 67 due to active LN, low proteinuria or low eGFR. Thirty patients were randomized: 14 to start the treatment with dapagliflozin on top of SoC therapy and 16 to remain with the usual therapy for 6 months. Nine patients were excluded from the analysis due to new LN flares or lost to follow-up. We demonstrate a significant reduction in residual proteinuria in patients with inactive LN with dapagliflozin without safety concerns.

Category

Transplant

Source

Nephrology Dialysis Transplantation

Read the original article

More from ASNRT News

Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.

All news · ASNRT home